Diamond Hill Capital Management Inc. raised its position in shares of Perrigo Company plc (NYSE:PRGO - Free Report) by 0.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,894,739 shares of the company's stock after buying an additional 11,256 shares during the quarter. Diamond Hill Capital Management Inc. owned 1.39% of Perrigo worth $53,128,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC grew its holdings in shares of Perrigo by 1,942.0% during the fourth quarter. Headlands Technologies LLC now owns 1,409 shares of the company's stock valued at $36,000 after buying an additional 1,340 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of Perrigo by 176.9% in the 1st quarter. Parallel Advisors LLC now owns 1,714 shares of the company's stock valued at $48,000 after purchasing an additional 1,095 shares during the period. First Horizon Advisors Inc. boosted its holdings in shares of Perrigo by 138.3% during the first quarter. First Horizon Advisors Inc. now owns 1,754 shares of the company's stock worth $49,000 after purchasing an additional 1,018 shares during the period. Fifth Third Bancorp increased its stake in Perrigo by 62.0% in the 1st quarter. Fifth Third Bancorp now owns 2,218 shares of the company's stock valued at $62,000 after buying an additional 849 shares during the period. Finally, Blue Trust Inc. lifted its position in Perrigo by 110.4% in the 1st quarter. Blue Trust Inc. now owns 2,619 shares of the company's stock worth $73,000 after buying an additional 1,374 shares in the last quarter. Institutional investors and hedge funds own 95.91% of the company's stock.
Analysts Set New Price Targets
Separately, Wall Street Zen raised shares of Perrigo from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $33.00.
Read Our Latest Stock Report on Perrigo
Perrigo Stock Down 0.0%
NYSE PRGO traded down $0.00 during trading on Thursday, reaching $28.12. The company's stock had a trading volume of 668,841 shares, compared to its average volume of 857,294. The company has a current ratio of 2.36, a quick ratio of 1.28 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $3.87 billion, a PE ratio of -21.46 and a beta of 0.45. Perrigo Company plc has a 1-year low of $23.14 and a 1-year high of $30.93. The business has a 50-day moving average price of $26.93 and a 200-day moving average price of $26.18.
Perrigo (NYSE:PRGO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.56 by $0.04. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a positive return on equity of 8.93% and a negative net margin of 4.16%. The firm's revenue was down 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.29 EPS. On average, research analysts forecast that Perrigo Company plc will post 2.56 earnings per share for the current fiscal year.
Perrigo Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 17th. Stockholders of record on Friday, May 30th were given a $0.29 dividend. The ex-dividend date of this dividend was Friday, May 30th. This represents a $1.16 annualized dividend and a dividend yield of 4.13%. Perrigo's dividend payout ratio is -88.55%.
About Perrigo
(
Free Report)
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Recommended Stories

Before you consider Perrigo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perrigo wasn't on the list.
While Perrigo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.